Patterns of long-term thienopyridine therapy and outcomes in patients with acute coronary syndrome treated with coronary stenting: Observations from the timi-38 coronary stent registry

Clinical Cardiology

Volumn 37, Issue 5, 2014, Pages 293-299

  Bonaca, Marc P ^a   Murphy, Sabina A ^a   Miller, Debra ^b   Herrman, Jean Paul R ^c   Gottlieb, Shmuel ^d   Keltai, Matyas ^e   Menozzi, Alberto ^f   Nicolau, José C ^g   Widimsky, Petr ^h   Antman, Elliott M ^a   Wiviott, Stephen D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c Department of Cardiology Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^d TEL AVIV UNIVERSITY   (Israel)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g UNIVERSITY OF SÃO PAULO   (Brazil)

^h CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; PYRIDINE DERIVATIVE; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; BARE METAL STENT; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; EASTERN EUROPE; EVENT FREE SURVIVAL; FEMALE; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NORTH AMERICA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REGISTER; SOUTH AMERICA; TREATMENT DURATION; WESTERN EUROPE; CLINICAL TRIAL; COMPLICATION; FOLLOW UP; HEMORRHAGE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MYOCARDIAL INFARCTION; PROSPECTIVE STUDY; STENT; STROKE; SURVIVAL; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; PYRIDINES; REGISTRIES; STENTS; STROKE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84900827793     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22247     Document Type: Article

References (20)

1. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502.
2. Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366: 1622-1632.
3. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005; 352: 1179-1189.
4. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706-1717.
5. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49: 1982-1988.
6. James SK, Stenestrand U, Lindback J, et al. Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden. N Engl J Med. 2009; 360: 1933-1945.
7. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006; 48: 2584-2591.
8. Valgimigli M, Campo G, Monti M, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012; 125: 2015-2026.
9. Park SJ, Park DW, Kim YH, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010; 362: 1374-1382.
10. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to review new evidence and update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee [published correction appears in Circulation. 2008;117:e162]. Circulation. 2008; 117: 296-329.
11. Wiviott SD, Antman EM, Gibson CM, et al. TRITON-TIMI 38 Investigators. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel- Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006; 152: 627-635.
12. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015.
13. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007; 356: 1020-1029.
14. Bavry AA, Kumbhani DJ, Helton TJ, et al. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006; 119: 1056-1061.
15. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007; 369: 667-678.
16. Rodriguez F, Cannon CP, Steg PG, et al. for REACH Registry Investigators. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH registry. Clin Cardiol. 2013; doi: 10.1002/clc22217.
17. Mauri L, Kereiakes DJ, Normand SL, et al. Rationale and design of the Dual Antiplatelet Therapy Study: a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare-metal stent placement for the treatment of coronary artery lesions. Am Heart J. 2010; 160: 1035-1041, 1041.e1.
18. Reed GW, Cannon CP,. Triple oral antithrombotic therapy in atrial fibrillation and coronary artery stenting. Clin Cardiol. 2013; 36: 585-594.
19. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366: 1404-1413.
20. Scirica BM, Bonaca MP, Braunwald E, et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2P-TIMI 50 trial. Lancet. 2012; 380: 1317-1324.